|
February 2025 KL-50 IN POST-TMZ MMR-DEFICIENT GLIOBLASTOMACraig M. Horbinski, MD, PhD, of Northwestern Medicine, joins Neuro-Oncology: The Podcast where he was interviewed by Iyad Alnahhas, MD, from Thomas Jefferson University. Dr. Horbinski discusses his team's manuscript, "The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma," published in Neuro-Oncology. Listen to the podcast > |
Refer a PatientNorthwestern Medicine welcomes the opportunity to collaborate with you on the care of your patients.
|
You May Also Like
|
|
|